# A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

> **NCT05071183** · PHASE1,PHASE2 · TERMINATED · sponsor: **Turning Point Therapeutics, Inc.** · enrollment: 9 (actual)

## Conditions studied

- KRAS Mutation-Related Tumors
- Metastatic Solid Tumor
- Advanced Solid Tumor

## Interventions

- **DRUG:** TPX-0005
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT05071183
- **Lead sponsor:** Turning Point Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-23
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Inability to achieve and optimize a dose that could provide a positive benefit risk profile
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05071183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05071183, "A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05071183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*